Site search
2831 results for '' found
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Deucravacitinib (BMS-986165) in Participants with Active Discoid and/or Subacute Cutaneous Lupus Er
A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Evaluate Efficacy and Safety of Deucravacitinib (BMS-986165) in Participants with Active Discoid and/or Subacute Cutaneous Lupus Er
/
Bend to Limit oxygEN in ECMO: a ranDomised controllEd Registry trial. (NCT03841084)
Bend to Limit oxygEN in ECMO: a ranDomised controllEd Registry trial. (NCT03841084)
/
A Phase 1/2a, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of BJT-778 in Healthy Volunteers and in Subjects with Chronic Hep
A Phase 1/2a, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of BJT-778 in Healthy Volunteers and in Subjects with Chronic Hep
/
A Study to Evaluate Cavrotolimod in Subjects with Chronic Hepatitis B Virus [HBV] Infection (ACTRN12624000809538)
A Study to Evaluate Cavrotolimod in Subjects with Chronic Hepatitis B Virus [HBV] Infection (ACTRN12624000809538)
/
BiVACOR® Total Artificial Heart Clinical Feasibility Study (ACTRN12624001379505)
BiVACOR® Total Artificial Heart Clinical Feasibility Study (ACTRN12624001379505)
/
Lunsayil LTE: An extension trial assessing long-term spesolimab treatment in patients with Hidradenitis Suppurativa (HS) (NCT06241573)
Lunsayil LTE: An extension trial assessing long-term spesolimab treatment in patients with Hidradenitis Suppurativa (HS) (NCT06241573)
/
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of BGB-C354, an Antibody-Drug Conjugate Targeting B7H3, Alone and in Combination With
/
BHV3000-406: A Phase 4, Randomized, Doubleblind Placebo-Controlled, Efficacy and TolerabilityTrial of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use (NCT05509
BHV3000-406: A Phase 4, Randomized, Doubleblind Placebo-Controlled, Efficacy and TolerabilityTrial of Rimegepant for the Acute Treatment of Migraine in Adults Unsuitable for Triptan Use (NCT05509
/
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B167, Alone and in Combination With Tislelizumab in Pati
A Phase 1a/1b Study Investigating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Antitumor Activity of BGB-B167, Alone and in Combination With Tislelizumab in Pati
/
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabin
A Phase 1b/2, Randomized, Open-Label Study Investigating the Efficacy and Safety of LBL-007 Plus Tislelizumab in Combination With Bevacizumab Plus Capecitabine Versus Bevacizumab Plus Capecitabin
/